Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir

Antiviral Res. 1995 May;27(1-2):171-8. doi: 10.1016/0166-3542(94)00081-i.

Abstract

In order to define, in more detail, the virological events which occur after completion of antiviral chemotherapy, ducks congenitally infected with the duck hepatitis B virus (DHBV) were treated for 4 weeks with the nucleoside analogue ganciclovir and followed up over a 7-day period. Specimens of serum and liver were collected daily during follow-up for virological analysis. Treatment resulted in a substantial reduction in both viraemia and liver DHBV DNA replicative intermediates. However, after cessation of treatment, viraemia returned to detectable levels within 4 days. In the liver, the viral supercoiled DNA (SC DNA) was the form least affected by therapy and returned to near control levels by day 2 post-treatment. The other hepatic replicative intermediates reached pretreatment levels within 4 days of cessation of therapy. This study has defined the kinetics of relapse of viral replication after completion of antiviral therapy in the duck hepatitis B model. Of all viral replicative forms, the SC DNA appears to be the one which is most resistant to nucleoside analogue therapy and is presumably responsible for the relapse phenomenon observed post-treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • DNA Replication / drug effects*
  • DNA, Viral / biosynthesis
  • DNA, Viral / blood
  • DNA, Viral / drug effects*
  • Ganciclovir / pharmacology*
  • Hepadnaviridae Infections / blood
  • Hepadnaviridae Infections / drug therapy*
  • Hepadnaviridae Infections / virology
  • Hepatitis B Virus, Duck / drug effects*
  • Hepatitis B Virus, Duck / genetics
  • Hepatitis B Virus, Duck / physiology
  • Liver / virology
  • Nucleosides / therapeutic use
  • Virus Replication / drug effects*

Substances

  • DNA, Viral
  • Nucleosides
  • Ganciclovir